Target intelligence / Profile preview

L-type calcium channel CaV1.2 (vascular smooth muscle isoform) (CaV1.2)

Target
CaV1.2
Molecular classification
Ion channel
01

Overview

The L-type calcium channel CaV1.2 (vascular smooth muscle isoform) is a voltage-gated ion channel that serves as the primary pathway for Ca2+ influx in vascular smooth muscle cells (VSMCs), enabling membrane depolarization-induced contraction and maintenance of myogenic tone. Composed of a pore-forming α1C (CaV1.2) subunit along with auxiliary β (predominantly β3), α2δ, and γ subunits, it forms heteromeric complexes that regulate channel trafficking, gating, and Ca2+ selectivity. Activation occurs at depolarized potentials typical of VSMCs, coupling pressure or agonist-induced depolarization to Ca2+ entry that triggers contraction via calmodulin and RhoA pathways. It is essential for autoregulation of blood flow, phenylephrine- or angiotensin II-induced vasoconstriction, and blood pressure control, as evidenced by smooth muscle-specific knockout studies showing abolished L-type currents, blunted vasoconstriction, and reduced myogenic responses. In disease, dysregulation contributes to hypertension and vascular hypercontractility; its expression correlates with VSMC differentiation markers like SM α-actin and myosin heavy chain. Therapeutically, it is targeted by calcium channel blockers (e.g., dihydropyridines) that inhibit Ca2+ entry to promote vasodilation, though challenges include isoform-specific regulation and off-target effects on cardiac channels.

Other names
L-type Ca2+ channelLTCCvoltage-dependent L-type calcium channelCaV1.2 channel
02

Mechanism of action

Calcium channel blockade inhibiting Ca2+ influx to reduce vascular smooth muscle contraction and blood pressure, Voltage-dependent inhibition of Ca2+ current

03

Biological functions

Vascular smooth muscle contractionMyogenic tone regulationElectromechanical couplingGene expression
04

Disease associations

Cardiovascular diseaseHypertension
05

Safety considerations

Excessive blockade may cause hypotensionbradycardiaor reflex tachycardiapotential for constipation or edema with certain blockers
06

Interacting drugs

Dihydropyridines (e.g., calcium channel blockers)

2 more in the full profile.

Beyond the preview

Go deeper on L-type calcium channel CaV1.2 (vascular smooth muscle isoform) (CaV1.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-type calcium channel CaV1.2 (vascular smooth muscle isoform) (CaV1.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call